Development of WT1 peptide-based immunotherapy for inoperable thoracic malignant tumors, and analysis of immunodynamics of the novel therapy

2014 Fiscal Year Final Research Report

• Project/Area Number: 24591164
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Osaka University
• Principal Investigator: OKA Yoshihiro 大阪大学, 医学(系)研究科(研究院), 特任教授 (20273691)
• Co-Investigator(Kenkyū-buntansha): TAKEDA Yoshito 大阪大学, 医学(系)研究科(研究院), 助教 (40452388) ; TAKAHASHI Ryo 大阪大学, 医学(系)研究科(研究院), 助教 (10546865) ; NAGATOMO Izumi 大阪大学, 医学(系)研究科(研究院), 助教 (10570583) ; OTSUKA Tomoyuki 大阪大学, 医学部付属病院, 特任助教 (20730576)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: WT1 / 免疫治療 / 悪性腫瘍 / T細胞レセプター / CTL / ペプチドワクチン / 癌抗原 / Th17

Outline of Final Research Achievements

In order to molecularly analyze cancer antigen WT1-specific immune response, we cloned a gene for T cell receptor that recognizes WT1-CTL(cytotoxic T lymphocyte) peptide with the restriction of HLA class I, and two distinct genes for those that recognize WT1-helper peptide with the restriction of HLA class II, respectively. We identified WT1-specific Th17 cells with helper function. Using the method for comprehensive analysis of gene expression profiles at a single cell level, we found that there are molecularly distinct two subpopulations in effector-memory subset of WT1-specific CTLs in peripheral blood mononuclear cells of acute myeloid leukemia patients.
We successively performed WT1 peptide-based immunotherapy (WT1 peptide vaccine) for patients with malignancies, including inoperable thoracic malignant tumors.

Free Research Field

腫瘍免疫学